Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Leukemia 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lung Neoplasms 2Congenital Abnormalities 2Thymoma 1Sarcoma, Ewing 1Sarcoma 1Rare Diseases 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Plasma Cell 1Neoplasms, Connective and Soft Tissue 1Neoplasms, Connective Tissue 1Neoplasms, Bone Tissue 1Neoplasms by Histologic Type 1Neoplasms 1Multiple Myeloma 1Mesothelioma 1Melanoma 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myeloid, Acute 1Esophageal Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide 2Celecoxib 2selinexor 1saracatinib 1TP protocol 1FANG vaccine 1Doxepin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Thymoma × FANG vaccine × Clear all
NCT01258868 2019-12-03

Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
44 enrolled
GastrointestinalOther solid neoplasmThoracic

Esophageal Neoplasms, Lung Neoplasms, Mesothelioma, Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡